| Abstract: | Systemic lupus erythematosus and subacute cutaneous lupus erythematosus (SCLE) occasionally evolve as adverse reactions to a large variety of chemically different drugs. We here report on a 76‐year‐old woman who developed SCLE within 10 days after initiation of oral terbinafine. Analysis of the 27 cases of terbinafine‐induced SCLE in the literature revealed that this disorder has been reported 6 times more often in females than in males. Skin lesions evolved on average around 7 weeks after starting the drug. In 79% of the cases ANA could be detected while antibodies against Ro/SS‐A and La/SS‐B were found in 86% and 39%, respectively. Remarkably, anti‐histone antibodies were present in only 29%. In all cases terbinafine‐induced SCLE resolved after discontinuation of the triggering agent. Systemic treatment with anti‐malarials and/or corticosteroids does not appear to be mandatory. |
